AI Predicts a Bearish Trend for Incyte Corp: A Potential 4% Monthly Decline Ahead
In the world of trading, the ability to anticipate market movements is invaluable. Our AI has identified a bearish trend for Incyte Corp (INCY, $60.97), predicting a decline of 4% to $58.53 or more within the next month. Based on similar scenarios where the stock trended down during the month, the odds of a downtrend continuation are 84%.
Experience the future of trading with Tickeron's cutting-edge AI robots, revolutionizing decision-making processes.
Incyte Corp operates within the biotechnology industry, a sector that involves genetic or protein engineering to produce medicines and therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. However, these discoveries must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Some of the biggest operators in this industry include Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation.
In terms of market capitalization, the average across the Biotechnology Industry is 2.05B, with a range from 402 to 345.46B. NONOF holds the highest valuation in this group at 345.46B, while PNEXF is at the lower end with 402.
Looking at price growth, the average weekly growth across all stocks in the Biotechnology Industry was 2%, with a monthly growth of 5%, and a quarterly growth of 31%. GLWLF experienced the highest price growth at 410%, while AVTX experienced the biggest fall at -89%.
In terms of volume, the average weekly volume growth across all stocks in the industry was 14%, with a monthly volume growth of 39% and a quarterly volume decline of -59%.
AI's prediction of a bearish trend for Incyte Corp underscores the power of AI in predicting market trends. As we continue to refine our AI algorithms, we look forward to sharing more insights and predictions with you. Stay tuned!
Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.
INCY in +1.88% Uptrend, growing for three consecutive days on July 17, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INCY advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In of 238 cases where INCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for INCY moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where INCY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for INCY turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INCY broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.114) is normal, around the industry mean (20.302). P/E Ratio (16.355) is within average values for comparable stocks, (37.580). INCY's Projected Growth (PEG Ratio) (11.891) is very high in comparison to the industry average of (2.487). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (4.382) is also within normal values, averaging (395.736).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs
Industry Biotechnology
Advertisement